Inventor · disambiguated record
Yukio Tada
Also filed as: TADA YUKIO
21 granted patents·4 pending applications·281 citations·filing 1984–2019
95Inventor score
Top patents by PatentIndex Score
25 records- 0191US5744475AUracil derivatives, and antitumor effect potentiator and antitumor agent containing the sameTAIHO PHARMACEUTICAL CO LTD·Filed 1996·Granted Apr 28, 1998·47 cites·14 claims
- 0291US4556737ASulfonium compounds, processes for preparing the compounds and pharmacological composiitons containing the sameTAIHO PHARMACEUTICAL CO LTD·Filed 1984·Granted Dec 3, 1985·39 cites·9 claims
- 0390US6977266B2Pyridone derivatives having affinity for cannabinoid 2-type receptorSHIONOGI & CO·Filed 2001·Granted Dec 20, 2005·45 cites·17 claims
- 0486US6159969AUracil derivatives, and antitumor effect potentiator and antitumor agent containing the sameTAIHO PHARMACEUTICAL CO LTD·Filed 1998·Granted Dec 12, 2000·31 cites·14 claims
- 0584US8168630B2Aminodihydrothiazine derivatives substituted with a cyclic groupTAMURA YUUSUKE·Filed 2008·Granted May 1, 2012·14 cites·12 claims
- 0678US9150546B2Triazine derivative and pharmaceutical composition comprising the sameKAI HIROYUKI·Filed 2010·Granted Oct 6, 2015·5 cites·5 claims
- 0778US7652141B2Pyridone derivatives having a binding activity to the cannabinoid type 2 receptorSHIONOGI & CO·Filed 2005·Granted Jan 26, 2010·3 cites·7 claims
- 0878US6294535B1Uracil derivatives and antitumor effect potentiator and antitumor agent containing the sameTAIHO PHARMACEUTICAL CO LTD·Filed 1999·Granted Sep 25, 2001·33 cites·15 claims
- 0973US10513513B2Salts of quinazoline derivative or crystals thereof, and the process for producing thereofSHIONOGI & CO·Filed 2019·Granted Dec 24, 2019·1 cites·6 claims
- 1072US9572813B2Antiviral agentSHIONOGI & CO·Filed 2015·Granted Feb 21, 2017·1 cites·11 claims
- 1171US10329285B2Salts of quinazoline derivative or crystals thereof, and the process for producing thereofSHIONOGI & CO·Filed 2016·Granted Jun 25, 2019·1 cites·16 claims
- 1270US8541408B2Aminodihydrothiazine derivatives substituted with a cyclic groupTAMURA YUUSUKE·Filed 2012·Granted Sep 24, 2013·2 cites·10 claims
- 1361US5883121AEpoxysuccinamide derivative or salt thereof, and medicine comprising the sameTAIHO PHARMACEUTICAL CO LTD·Filed 1996·Granted Mar 16, 1999·19 cites·10 claims
- 1460US8088924B2Pyridone derivatives having a binding activity to the cannabinoid type 2 receptorTADA YUKIO·Filed 2009·Granted Jan 3, 2012·0 cites·7 claims
- 1558US6110967AEpoxysuccinamide derivative or salt thereofTAIHO PHARMACEUTICALS CO LTD·Filed 1998·Granted Aug 29, 2000·18 cites·23 claims
- 1657US2017066754A1Antiviral agentSHIONOGI & CO·Filed 2016·Application pending·0 cites
- 1752US8884062B2Aminodihydrothiazine derivatives substituted with a cyclic groupSHIONOGI & CO·Filed 2013·Granted Nov 11, 2014·0 cites·4 claims
- 1852US6319902B1Peptide derivatives having thiazolyl-alanine residueSHIONOGI & CO·Filed 1997·Granted Nov 20, 2001·16 cites·14 claims
- 1946US4670583AAmide compoundsTAIHO PHARMACEUTICAL CO LTD·Filed 1985·Granted Jun 2, 1987·4 cites·8 claims
- 2046US2004229909A1Antiviral agentFiled 2002·Application pending·0 cites
- 2142US7919623B2Naphthyridine derivatives having inhibitory activity against HIV integraseSHIONOGI & CO·Filed 2005·Granted Apr 5, 2011·0 cites·6 claims
- 2241US9688643B2Triazine derivative and pharmaceutical composition comprising the sameSHIONOGI & CO·Filed 2015·Granted Jun 27, 2017·0 cites·4 claims
- 2337US4946951A2'-deoxy-5-fluorouridine derivativesTAIHO PHARMACEUTICAL CO LTD·Filed 1988·Granted Aug 7, 1990·2 cites·22 claims
- 2437US2012245154A1Substituted aminothiazine derivativeANAN KOUSUKE·Filed 2010·Application pending·0 cites
- 2531US2014235626A1Pyridine derivatives and a pharmaceutical composition for inhibiting bace1 containing themTADA YUKIO·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yukio Tada files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →